Antisense p53 transduction leads to overexpression of bcl-2 and dexamethasone resistance in multiple myeloma

Rajaraman Iyer, LieMing Ding, Ramesh B. Batchu, Willscott (Scott) Naugler, Masood A. Shammas, Nikhil C. Munshi

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Multiple myeloma is a malignant proliferation of plasma cells which fail to undergo apoptosis. To understand events associated with lack of apoptosis in these cells, we studied effect of antisense p53 gene transduction in a multiple myeloma cell line, ARH77. Adeno-associated virus was used as a vector to introduce p53 cDNA in an antisense orientation driven by a herpes virus thymidine kinase promoter. We observed, that an antisense p53 (p53as) transduced cell line showed marked reduction in p53 mRNA and protein expression and increased growth when compared to the control cell lines transduced with neomycin-resistance gene or untransduced cells. There was a concomitant up-regulation of bcl-2 expression by over five-fold in p53as-transduced cells compared with controls; while there was no significant change in expression of c-myc and IL-6, genes implicated in myeloma growth. We measured apoptosis in the transduced cells by DNA end-labeling reaction which revealed decrease in apoptosis from 15.6% in control cells to 1.6% in p53as-transduced cells. Additionally, the p53as cells over expressing bcl-2 also showed resistance to killing by dexamethasone. In summary, our data demonstrates that loss of p53 function leads to myeloma cell progression and resistant phenotype through bcl-2-related mechanisms.

Original languageEnglish (US)
Pages (from-to)73-78
Number of pages6
JournalLeukemia Research
Volume27
Issue number1
DOIs
StatePublished - Jan 1 2003
Externally publishedYes

Fingerprint

Multiple Myeloma
Dexamethasone
Apoptosis
Cell Line
Dependovirus
Neomycin
Thymidine Kinase
p53 Genes
Growth
Plasma Cells
Genes
Interleukin-6
Up-Regulation
Complementary DNA
Viruses
Phenotype
Messenger RNA
DNA
Proteins

Keywords

  • Apoptosis
  • bcl-2
  • Dexamethasone resistance
  • Multiple myeloma
  • p53

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Antisense p53 transduction leads to overexpression of bcl-2 and dexamethasone resistance in multiple myeloma. / Iyer, Rajaraman; Ding, LieMing; Batchu, Ramesh B.; Naugler, Willscott (Scott); Shammas, Masood A.; Munshi, Nikhil C.

In: Leukemia Research, Vol. 27, No. 1, 01.01.2003, p. 73-78.

Research output: Contribution to journalArticle

Iyer, Rajaraman ; Ding, LieMing ; Batchu, Ramesh B. ; Naugler, Willscott (Scott) ; Shammas, Masood A. ; Munshi, Nikhil C. / Antisense p53 transduction leads to overexpression of bcl-2 and dexamethasone resistance in multiple myeloma. In: Leukemia Research. 2003 ; Vol. 27, No. 1. pp. 73-78.
@article{ed48dc93c7484a91a16f156c523322be,
title = "Antisense p53 transduction leads to overexpression of bcl-2 and dexamethasone resistance in multiple myeloma",
abstract = "Multiple myeloma is a malignant proliferation of plasma cells which fail to undergo apoptosis. To understand events associated with lack of apoptosis in these cells, we studied effect of antisense p53 gene transduction in a multiple myeloma cell line, ARH77. Adeno-associated virus was used as a vector to introduce p53 cDNA in an antisense orientation driven by a herpes virus thymidine kinase promoter. We observed, that an antisense p53 (p53as) transduced cell line showed marked reduction in p53 mRNA and protein expression and increased growth when compared to the control cell lines transduced with neomycin-resistance gene or untransduced cells. There was a concomitant up-regulation of bcl-2 expression by over five-fold in p53as-transduced cells compared with controls; while there was no significant change in expression of c-myc and IL-6, genes implicated in myeloma growth. We measured apoptosis in the transduced cells by DNA end-labeling reaction which revealed decrease in apoptosis from 15.6{\%} in control cells to 1.6{\%} in p53as-transduced cells. Additionally, the p53as cells over expressing bcl-2 also showed resistance to killing by dexamethasone. In summary, our data demonstrates that loss of p53 function leads to myeloma cell progression and resistant phenotype through bcl-2-related mechanisms.",
keywords = "Apoptosis, bcl-2, Dexamethasone resistance, Multiple myeloma, p53",
author = "Rajaraman Iyer and LieMing Ding and Batchu, {Ramesh B.} and Naugler, {Willscott (Scott)} and Shammas, {Masood A.} and Munshi, {Nikhil C.}",
year = "2003",
month = "1",
day = "1",
doi = "10.1016/S0145-2126(02)00064-4",
language = "English (US)",
volume = "27",
pages = "73--78",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "1",

}

TY - JOUR

T1 - Antisense p53 transduction leads to overexpression of bcl-2 and dexamethasone resistance in multiple myeloma

AU - Iyer, Rajaraman

AU - Ding, LieMing

AU - Batchu, Ramesh B.

AU - Naugler, Willscott (Scott)

AU - Shammas, Masood A.

AU - Munshi, Nikhil C.

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Multiple myeloma is a malignant proliferation of plasma cells which fail to undergo apoptosis. To understand events associated with lack of apoptosis in these cells, we studied effect of antisense p53 gene transduction in a multiple myeloma cell line, ARH77. Adeno-associated virus was used as a vector to introduce p53 cDNA in an antisense orientation driven by a herpes virus thymidine kinase promoter. We observed, that an antisense p53 (p53as) transduced cell line showed marked reduction in p53 mRNA and protein expression and increased growth when compared to the control cell lines transduced with neomycin-resistance gene or untransduced cells. There was a concomitant up-regulation of bcl-2 expression by over five-fold in p53as-transduced cells compared with controls; while there was no significant change in expression of c-myc and IL-6, genes implicated in myeloma growth. We measured apoptosis in the transduced cells by DNA end-labeling reaction which revealed decrease in apoptosis from 15.6% in control cells to 1.6% in p53as-transduced cells. Additionally, the p53as cells over expressing bcl-2 also showed resistance to killing by dexamethasone. In summary, our data demonstrates that loss of p53 function leads to myeloma cell progression and resistant phenotype through bcl-2-related mechanisms.

AB - Multiple myeloma is a malignant proliferation of plasma cells which fail to undergo apoptosis. To understand events associated with lack of apoptosis in these cells, we studied effect of antisense p53 gene transduction in a multiple myeloma cell line, ARH77. Adeno-associated virus was used as a vector to introduce p53 cDNA in an antisense orientation driven by a herpes virus thymidine kinase promoter. We observed, that an antisense p53 (p53as) transduced cell line showed marked reduction in p53 mRNA and protein expression and increased growth when compared to the control cell lines transduced with neomycin-resistance gene or untransduced cells. There was a concomitant up-regulation of bcl-2 expression by over five-fold in p53as-transduced cells compared with controls; while there was no significant change in expression of c-myc and IL-6, genes implicated in myeloma growth. We measured apoptosis in the transduced cells by DNA end-labeling reaction which revealed decrease in apoptosis from 15.6% in control cells to 1.6% in p53as-transduced cells. Additionally, the p53as cells over expressing bcl-2 also showed resistance to killing by dexamethasone. In summary, our data demonstrates that loss of p53 function leads to myeloma cell progression and resistant phenotype through bcl-2-related mechanisms.

KW - Apoptosis

KW - bcl-2

KW - Dexamethasone resistance

KW - Multiple myeloma

KW - p53

UR - http://www.scopus.com/inward/record.url?scp=0037212602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037212602&partnerID=8YFLogxK

U2 - 10.1016/S0145-2126(02)00064-4

DO - 10.1016/S0145-2126(02)00064-4

M3 - Article

C2 - 12479855

AN - SCOPUS:0037212602

VL - 27

SP - 73

EP - 78

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 1

ER -